Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances

Executive Summary

A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products
Advertisement

Related Content

Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan
Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan
FDA “Failure” To Approve Generic Biologics Questioned By Commerce Cmte.
FDA “Failure” To Approve Generic Biologics Questioned By Commerce Cmte.
Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
Sandoz Omnitrope NDA Is Test For Follow-On Biologics; Pfizer Says No
Advertisement
UsernamePublicRestriction

Register

PS047471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel